Scinai Immunotherapeutics (SCNI) Operating Leases (2019 - 2026)

Scinai Immunotherapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Operating Leases rose 86.85% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.9 million (up 86.85% YoY), while the FY2025 annual figure was $1.6 million, up 17.26% from the prior year.
• Operating Leases came in at $2.9 million for Q2 2026 at Scinai Immunotherapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.9 million in Q2 2026 to a low of $583000.0 in Q3 2024.
• Average Operating Leases over 5 years is $1.4 million, with a median of $1.2 million recorded in 2022.
• Year-over-year, Operating Leases slumped 73.84% in 2022 and surged 144.69% in 2025.
• Over 5 years, Operating Leases stood at $1.1 million in 2022, then dropped by 26.07% to $797000.0 in 2023, then jumped by 75.91% to $1.4 million in 2024, then rose by 17.26% to $1.6 million in 2025, then surged by 77.98% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $2.9 million in Q2 2026, $2.9 million in Q1 2026, and $1.6 million in Q4 2025.